UK: NICE published draft guidance in which enzalutamide is not recommended as a drug to treat advanced prostate cancer. It says enzalutamide. also called Xtandi, manufactured by Astellas Pharma) is not a cost effective, pre chemotherapy treatment with too many uncertainties associated with evidence provided by manufacturer. …more
